Biological
Closed. Please see Biological100
Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness February 2013 (WHO)
http://www.who.int/influenza/vaccines/virus/201302_h5h7h9_vaccinevirusupdate.pdf
Highlights:
New 2013 Human Stain Designations
1. A/Cambodia/X0123311/2013 (HA clade 1.1)
2. A/Cambodia/X0123312/2013 (HA clade 1.1)
Both Cambodian designations are closely related to A/Vietnam/VP12-3/2012 (18year old Male duck worker in January 2012 from Ki?n Giang Province) and A/Duck/Cambodia/46W2M4/2013
Snip
Clade 1.1 viruses were detected in poultry and humans in Cambodia and in poultry in Viet Nam. Genetic characterization of the HA genes showed that these viruses were closely related to viruses detected previously in these countries (Figure 1) and which had reduced HI titres to post-infection ferret antisera raised against available candidate vaccine viruses. Antigenic analysis is ongoing and an additional candidate vaccine virus will be selected to provide improved coverage of recent clade 1.1 viruses.
-----------------------------------------------------------
3. A/Guizhou/1/2013 (HA clade 2.3.4.2)
4. A/Guizhou/2/2013 (HA clade 2.3.4.2)
Both Chinese designations are closely related to A/Guizhou/1/2012(39 Male from Guiyan City*in Jan 2012) and further related to A/Chicken/Guiyang/821/2011
Snip
Clade 2.3.4.2 viruses were isolated from humans in Guizhou province China. These viruses were genetically similar to A/Guizhou/1/2012 (Figure 3) and showed reduced HI titres with post-infection ferret antisera raised against the candidate vaccine viruses A/Anhui/1/2005 and A/chicken/Hong Kong/AP156/2008
Snip:
Based on the available antigenic, genetic and epidemiologic data, a new A/Guizhou/1/2013-like clade 2.3.4.2 candidate vaccine virus is proposed. The available and proposed candidate A(H5N1) vaccine viruses are listed in Table 4. On the basis of geographic spread, epidemiology and antigenic and genetic properties of the A(H5N1) viruses in particular locations, national authorities may consider the use of one or more of these candidate vaccine viruses for pilot lot vaccine production, clinical trials and other pandemic preparedness purposes.
See Figure 1, Figure 3; Table 4
http://www.who.int/influenza/vaccines/virus/201302_h5h7h9_vaccinevirusupdate.pdf
:tiphat:
http://www.who.int/influenza/vaccines/virus/201302_h5h7h9_vaccinevirusupdate.pdf
Highlights:
New 2013 Human Stain Designations
1. A/Cambodia/X0123311/2013 (HA clade 1.1)
2. A/Cambodia/X0123312/2013 (HA clade 1.1)
Both Cambodian designations are closely related to A/Vietnam/VP12-3/2012 (18year old Male duck worker in January 2012 from Ki?n Giang Province) and A/Duck/Cambodia/46W2M4/2013
Snip
Clade 1.1 viruses were detected in poultry and humans in Cambodia and in poultry in Viet Nam. Genetic characterization of the HA genes showed that these viruses were closely related to viruses detected previously in these countries (Figure 1) and which had reduced HI titres to post-infection ferret antisera raised against available candidate vaccine viruses. Antigenic analysis is ongoing and an additional candidate vaccine virus will be selected to provide improved coverage of recent clade 1.1 viruses.
-----------------------------------------------------------
3. A/Guizhou/1/2013 (HA clade 2.3.4.2)
4. A/Guizhou/2/2013 (HA clade 2.3.4.2)
Both Chinese designations are closely related to A/Guizhou/1/2012(39 Male from Guiyan City*in Jan 2012) and further related to A/Chicken/Guiyang/821/2011
Snip
Clade 2.3.4.2 viruses were isolated from humans in Guizhou province China. These viruses were genetically similar to A/Guizhou/1/2012 (Figure 3) and showed reduced HI titres with post-infection ferret antisera raised against the candidate vaccine viruses A/Anhui/1/2005 and A/chicken/Hong Kong/AP156/2008
Snip:
Based on the available antigenic, genetic and epidemiologic data, a new A/Guizhou/1/2013-like clade 2.3.4.2 candidate vaccine virus is proposed. The available and proposed candidate A(H5N1) vaccine viruses are listed in Table 4. On the basis of geographic spread, epidemiology and antigenic and genetic properties of the A(H5N1) viruses in particular locations, national authorities may consider the use of one or more of these candidate vaccine viruses for pilot lot vaccine production, clinical trials and other pandemic preparedness purposes.
See Figure 1, Figure 3; Table 4
http://www.who.int/influenza/vaccines/virus/201302_h5h7h9_vaccinevirusupdate.pdf
:tiphat: